

## PuriCore Arranges New \$20 Million Borrowing Facility

**MALVERN, PENNSYLVANIA, AND STAFFORD, UK, October 17, 2007**— [PuriCore](#) (LSE: PURI), the life sciences company focused on the control of infectious pathogens with its novel, safe antimicrobial technology, announces that it has arranged a new borrowing facility totaling \$20 million with Brown Brothers Harriman & Co. The new facility is a demand line of credit at the London Interbank Offered Rate (LIBOR) plus 1.75%. Approximately \$4.25 million of this facility will be used immediately to refinance existing debt, while the remainder of the line is available to fund purchases of new equipment and for general working capital.

“This facility provides flexible, cost-effective financing to support PuriCore’s business model and the underlying value of the Company,” said Keith A. Goldan, CFO of PuriCore. “The new line of credit enables us to refinance a portion of our previous debt at a lower cost of capital and on much improved terms. The additional capital allows us to take advantage of and finance the many new business development opportunities before us.”

### About PuriCore

[PuriCore](#) (LSE: PURI) is a life sciences company focused on developing and commercializing proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore’s technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, wound therapy, and hospitality. The Company’s proprietary technology mimics the human body’s production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying hypochlorous acid solutions as soaks, sprays, mists, and in other forms, PuriCore’s technology is designed to limit the spread of infectious disease, including major public health threats of *M. tuberculosis*, *MRSA*, *E.coli*, Norovirus, Avian Influenza, HIV, Polio Virus, *Helicobacter pylori*, and *Legionella*. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.

To receive additional information on PuriCore, please visit our website at [www.puricore.com](http://www.puricore.com), which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

**Contacts:**

Jennifer Guinan  
Sage Strategic Marketing  
[Jennifer@sagestrat.com](mailto:Jennifer@sagestrat.com)  
610-410-8111

Greg Bosch, CEO  
Keith A. Goldan, CFO  
PuriCore  
484 321 2700